|
Farré M, Roset PN, de la Torre R, Segura M, Ortuño J, Peiró A, Torrens M, Pacifici R, Zuccaro P, Camí J.
“Interaction of Paroxetine and MDMA in humans”.
College on Problems of Drug Dependence. 2002 Jun;Poster Board 100.
|
|
Abstract
A double-blind, randomized clinical trial was carried out to study the influence of paroxetine (a selective serotonin reuptake inhibitor and a potent inhibitor of hepatic CYP 2D6 isoenzyme) in the pharmacological effects and the pharmacokinetics of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy). The local Ethics Committee (CEIC-IMAS) and Spanish Medicines Control Agency approved the study protocol. A group of 10 recreational users of MDMA were included. Subjects were randomized to receive during three days paroxetine (20 mg once a day) or matched placebo. Three hours after the last paroxetine/placebo administration, subjects were given a pharmacological challenge with MDMA (100 mg oral). Study evaluations included physiological, subjective and psychomotor effects. Blood samples were drawn to determine MDMA and metabolites. Paroxetine reduced the physiological (blood pressure and heart rate) and subjective effects (euphoria) induced by the MDMA challenge. Paroxetine produced a slight increase MDMA plasma levels but reduced by half the formation of 4-hydroxy-3-methoxymethamphetamine (HMMA). Supported by grants: FIS 01/1336, CIRIT/2001/SGR/00407 and Istituto Superiore Sanità.
|
